A5048544543- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Sarcoma Diagnosis and Treatment
- Renal cell carcinoma treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Angiogenesis and VEGF in Cancer
- Cancer, Lipids, and Metabolism
- Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Nutrition, Genetics, and Disease
- Renal and related cancers
- Immunotherapy and Immune Responses
- Erythropoietin and Anemia Treatment
- Health, Medicine and Society
- Metastasis and carcinoma case studies
- Colorectal and Anal Carcinomas
- Melanoma and MAPK Pathways
- Chemokine receptors and signaling
- Management of metastatic bone disease
- Kidney Stones and Urolithiasis Treatments
- Lung Cancer Research Studies
- Nausea and vomiting management
AlterSanté
2009-2023
Institut National du Cancer
2021
Institution de Lavigny
2013
Sorbonne Université
2001-2011
Mount Sinai Medical Center
2011
Beth Israel Deaconess Medical Center
2011
Midwestern Regional Medical Center
2011
University of Cincinnati
2011
Pitié-Salpêtrière Hospital
2002-2011
Institut Gustave Roussy
2000-2010
<h3>Background</h3> Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant disorder predisposing humans to cutaneous uterine leiomyomas; in 20% of affected families, type 2 papillary cancers (PRCCII) also occur with aggressive course poor prognosis. HLRCC results from heterozygous germline mutations the tumour suppressor fumarate hydratase (<i>FH</i>) gene. <h3>Methods</h3> As part French National Cancer Institute (INCa) 'Inherited predispositions kidney cancer'...
This multicenter, open-label, phase II study evaluated the safety and clinical activity of axitinib, a potent selective second-generation inhibitor vascular endothelial growth factor receptors (VEGFR)-1, 2, 3, in patients with metastatic melanoma.Thirty-two maximum one prior systemic therapy received axitinib at starting dose 5 mg twice daily. The primary endpoint was objective response rate.Objective rate 18.8% [95% confidence interval (CI), 7.2-36.4], comprising complete five partial...
7541 Background: Overexpression of vascular endothelial growth factor receptor (VEGF-R) in NSCLC-tumors is linked to poor prognosis and shorter overall survival (OS). PTK/ZK a novel, oral, anti-angiogenic compound blocking all currently known VEGF receptors (VEGF-R 1–3). Methods: A prospective, single-arm, multi-center, proof-of-principle phase II study investigate efficacy safety pretreated pts with stage IIIB/IV NSCLC. Only one platinum-based chemotherapy regimen was allowed as first-line...
Biological response parameters during biochemotherapy, including chemotherapy with immune modulating agents, have been studied extensively. Of these parameters, interleukin-6 (IL-6) has implicated in advanced stage disease and tumour recurrence. However, there is limited information available about the significance of IL-6 metastatic malignant melanoma (MMM). In this study, we evaluated possible relationship between serum level overall survival. This retrospective study included 125 patients...
Purpose: To improve outcomes in localized osteosarcoma and to reduce the duration of preoperative chemotherapy, we conducted a phase ii trial assessing efficacy an intensive protracted regimen without methotrexate (API-AI regimen) adolescent adult patients with newly diagnosed disease. Patients Methods: Induction chemotherapy consisted 2 cycles (4 courses) doxorubicin 60 mg/m2 (days 1 15), cisplatin 100 (day 1), ifosfamide 5 g/m2 15). The primary endpoint was good histologic response [GHR...
This retrospective study sought to evaluate the impact of IL-6 concentration on time progression in advanced melanoma. One hundred and thirty-five patients were included, serum levels determined before (Day 0), at end treatment 49) recurrence: relationship between (TTP) was also evaluated. The baseline median level 16.5 pg/ml. When disease observed, an increase noted. In order establish possible TTP, divided into two groups (low high) using (16.5 pg/ml) detected pretreatment overall as a...
3003 Background: Significant activity of AG-013736, an oral small molecule with potent inhibitory effects against the VEGF receptors 1 (VEGFR-1) and 2 (VEGFR-2) PDGF receptor, is reported in a phase study metastatic RCC (Rini D. et al, ASCO 2005). Over 52 enrolled patients (pts), best response assessed by RECIST criteria 40% (21 partial responses. However, frequency stable disease clinical improvement lead to define new parameters therapeutic evaluation. The question was addressed 13 treated...
Delayed emesis following chemotherapy in cancer patients remains an important challenge for treatment and contributes to poor quality of life compliance.To compare the efficacy tolerability associations metopimazine ondansetron with methylprednisolone prevention delayed chemotherapy-induced nausea emesis.A randomised, open-label, observational, cross-over design was used two strategies consecutive sessions separated by at least 1 week. Patients were randomised sublingual (15 mg tid) or...